Alnitak program (Aqilion)

N/A

Report date: 2025/03/14 16:30:40
NME

Base Information

Drug NameAlnitak program (Aqilion)
Drug Alias NameTAK1 inhibitor (Aqilion)TGF-beta-activated kinase 1 inhibitor (Aqilion)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTGF-β activated kinase-1 inhibitors
TargetsTGF-β activated kinase-1
Therapy Area/IndicationsInflammationNervous System DiseasesArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAqilion AB
China Registration ClassN/A

Develop Information

Active CompaniesAqilion AB
Inactive CompaniesMerck KGaA, Darmstadt, Germany
Active IndicationsInflammationNervous System DiseasesArthritis, Rheumatoid +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A